Navigation Links
AtriCure Reports Third Quarter 2007 Financial Results
Date:11/6/2007

equivalents and short-term investments were $21.2 million at September 30, 2007 and there were 14.1 million shares of common stock outstanding.

Initial Human Implants - Left Atrial Appendage Clip System

In September 2007, AtriCure's left atrial appendage clip was successfully implanted during an open-heart surgical procedure. To date, as part of a European clinical study, AtriCure's left atrial appendage clip has been successfully implanted in a small series of patients during open-heart surgical procedures in Zurich, Switzerland.

Minimally Invasive Isolator Synergy(TM) System Released

During the quarter, AtriCure released its next generation minimally invasive clamp system, Isolator Synergy(TM). This system incorporates two pulsing pairs of electrodes in the jaws of the clamp. AtriCure believes this enhanced technology allows physicians to ensure full thickness ablations in thicker, more diseased tissues and creates more durable lines of block. The open-heart version was released during the first quarter of 2007 and has been widely adopted.

Financial Guidance

For the full year 2007, the Company is narrowing its revenue guidance range and lowering its net loss per share guidance. The Company expects annual 2007 revenues to be in the range of $48.0 to $48.7 million and net loss per share to be in the range of $0.92 to $0.97 per share. For the fourth quarter 2007, revenues are expected to be between $12.8 and $13.5 million.

Conference Call

AtriCure will host a conference call at 10:00 a.m. ET on Tuesday, November 6, 2007, to discuss third quarter 2007 results. A live web cast of the conference call will be available online from the investor relations page of AtriCure's corporate web site at http://www.atricure.com. Pre-registration is available for this call at the following URL:

SOURCE AtriCure, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
2. AtriCure to Present at Roth Capital Partners 2007 New York Conference
3. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
4. AtriCure to Present at ThinkEquity Partners 5th Annual Growth Conference
5. Published Results Using AtriCure Minimally Invasive Products
6. AtriCure Announces Web Cast and Conference Call of Third Quarter 2007 Financial Results
7. AtriCure Ranked 80th in Deloittes Technology Fast 500
8. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
9. Haemacure Reports Third Quarter 2007 Results
10. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
11. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2008)... Dr. Stephen Cohen Hired As New CEO, ATLANTA,...r Group,(GMCG) announced today that MELCO Investme...ment fund, has signed on as a key partner with a,s...the investment, GMCG has,also appointed Dr. Stephe...,surgeons, as its new CEO., (Photo: http://www.n...
(Date:7/23/2008)...d and Medicare Rules Highlighted; a Focus on Preve...tions, LANSING, Mich., July 23 /PRNewswire/ -- Th...&PSI), a national leader in clinical risk manageme... care institutions and,providers, today announced ... conference., The conference will take place Sept...
(Date:7/23/2008)... Michigan Takes Top Honors as the #1 Healthiest Ci...PRNewswire-USNewswire/ -- AARP The Magazine, the,d...largest-circulation,magazine with more than 34 mil...st cities to live and retire in with Ann Arbor, MI...go, ND taking the top five rankings.,Featured in t...
(Date:7/23/2008)...a., July 23 /PRNewswire-USNewswire/ -- The HealthC...m ) today announced that Dr. Fran Cogen,MD, direc...am at Children,s,National Medical Center, will pro...om, a site offering connections to a community of ...priate consultation by a dietician, social,worker,...
Breaking Medicine News(10 mins):Health News:Greater Medical Center Group Receives Major Funding From MELCO Investments 2Health News:Greater Medical Center Group Receives Major Funding From MELCO Investments 3Health News:The Risk Management and Patient Safety Institute Announces 2008/2009 Annual Risk Management Conference, Dates 2Health News:AARP the Magazine Names the Top 10 Healthiest Places to Live in America 2Health News:AARP the Magazine Names the Top 10 Healthiest Places to Live in America 3Health News:AARP the Magazine Names the Top 10 Healthiest Places to Live in America 4Health News:AARP the Magazine Names the Top 10 Healthiest Places to Live in America 5Health News:Children's National Medical Center Program Director to Provide Expertise to DiabeTeens.com, The HealthCentral Network's Teen Diabetes Site 2
... rampant felling of trees for construction purpose...sities in Delhi have raised their voice to save t...e students of Delhi University (DU) have forwarded...eepak Pental objecting to the plan to cut 1,000 tr...
...-enhanced ultrasound (CE-US) after a liver transpl... as biliary complications , according to a recent ... recipients who underwent a CE-US exam after devel...clear liver function tests. "Acute liver failure i...
...vely easy and reliable test is on the cards for pr...ening risks to expectant mothers and their babies...mplication which could kill hundreds of fetuses a ...a test. One in ten pregnancies is fraught with suc...
...niversity researchers seem to know what makes cert...nts. Colleagues from Edinburgh University and the ...losed in on the possible risk factors in premature... expose them to risks of cot death. Professors An...
Other Medicine News:Health News:Students Join Hands to Save Green Cover in Delhi 2Health News:Spit Test Kit on the Cards to Ascertain Pre-eclampsia Risk 2
(Date:7/22/2008)...ISBANE, Australia, July 22 /PRNewswire-FirstCall/ ... yesterday, the Board of Progen,Pharmaceuticals Li...t it,had discontinued the PI-88 phase 3 study in l...ion to develop its existing portfolio of compounds...itional compounds and,opportunities through Merger...
(Date:7/22/2008)...test awards under Therapeutics Development Initiat...tions to 23; next deadline January 20,2009, NEW ...f its mission to,speed delivery of transformative ... Michael J. Fox Foundation for Parkinson,s Researc... industry research teams. The awards,were granted ...
(Date:7/22/2008)...te-of-the-Art PET Study Confirms Tyrima Exhibits E...operties - - Results Support Initiation of P..., N.C., July 22 /- CeNeRx BioPharma,...ercializing innovative,treatments for diseases of ...to advance its lead candidate Tyrima(TM) into Phas...
(Date:7/22/2008)...UTH SAN FRANCISCO, Calif., July 22 /-...it has completed patient enrollment,in its Phase 1...lity and,ammonia scavenging effects of HPN-100 (fo...nylbutyrate) in patients with urea cycle disorders...ults in the fourth quarter,of this year., (Logo: ...
Breaking Medicine Technology:Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 2Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 3Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 2Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 3CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 2CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 3CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 4Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 2Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 3GlycoMark Blood Test Included in Global Diabetes Care Guidelines as Emerging Technology 1940 1GlycoMark Blood Test Included in Global Diabetes Care Guidelines as Emerging Technology 1940 2GlycoMark Blood Test Included in Global Diabetes Care Guidelines as Emerging Technology 1940 3Highlights of Economic and Business Growth in the Tampa Bay Region 800 1Highlights of Economic and Business Growth in the Tampa Bay Region 800 2Highlights of Economic and Business Growth in the Tampa Bay Region 800 3Highlights of Economic and Business Growth in the Tampa Bay Region 800 4Poll reveals public awareness of nanotech stuck at low level 1936 1Poll reveals public awareness of nanotech stuck at low level 1936 2Poll reveals public awareness of nanotech stuck at low level 1936 3Pelosi 3A Mr President Drop the Partisan Rhetoric Put Down the Veto Pen 1933 1
... - Dynogen,Pharmaceuticals, Inc. reported positive...controlled Phase 1b trial of DDP733 for,gastroesop...ed to,demonstrate proof-of-concept for DDP733 as a...dose of DDP733 achieved,statistical significance o...n the number of reflux events and was safe and wel...
... 2007 - Gilead,Sciences, Inc. (Nasdaq:GILD) today ...al evaluating the company,s once-daily,anti-HIV dr...vir,DF) 300 mg as a potential treatment for chroni...ry efficacy endpoint. The study shows,that Viread ...ral,drug Hepsera(R) (adefovir dipivoxil) among pat...
Other Medicine Technology:Dynogen Reports Positive Results in Phase 1B GERD Study 2Dynogen Reports Positive Results in Phase 1B GERD Study 3Dynogen Reports Positive Results in Phase 1B GERD Study 4Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 2Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 3Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 4Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 5Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 6Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 7
This stain is a classical hematology stain that requires a longer staining time but produces a very dense coloration. It is used in the staining of peripheral blood smears and bone marrows. The resul
Our Wright stain is a dual-use stain for peripheral blood and bone marrow smears. It produces results similar to those of the Giemsa stain with a slightly greater contrast.
Albumin reagent is used for the quantitative determination of albumin concentration in human serum.
AST (SGOT) reagent is used for the quantitative determination of aspartate aminotransferase (AST) in human serum.
Medicine Products: